Omlyclo (Omalizumab)

Omalizumab, the active ingredient in Omlyclo, is a monoclonal antibody presented as a strength/form for subcutaneous injection use. It treats moderate to severe persistent allergic asthma and chronic spontaneous urticaria in patients who are inadequately controlled by standard therapy. GNH USA supplies Omlyclo as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Omlyclo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omlyclo is a monoclonal antibody that targets IgE‑mediated pathways in allergic disease.

- Chronic spontaneous urticaria: reduces hives and itch severity. - Moderate to severe allergic asthma: improves lung function and decreases exacerbations. - Nasal polyposis associated with chronic sinusitis: helps shrink polyp size and relieve congestion. - Allergic rhinitis (seasonal): alleviates nasal congestion, sneezing and itching. - Atopic dermatitis: lessens skin inflammation and pruritus. - Food  t  ??

The        …  …  … ​ …  … ...